MOTS-c is a small peptide, just 16 amino acids long, produced by your mitochondria. Unlike most proteins in your body, which are encoded by DNA in the cell nucleus, MOTS-c is encoded by a specific gene in the mitochondrial genome called the 12S rRNA gene. It acts as a signaling molecule that travels through the bloodstream and influences how your body processes sugar, stores fat, builds bone, and responds to exercise. Think of it as a chemical messenger your mitochondria send out to keep your metabolism running smoothly.
How Mitochondria Produce MOTS-c
Your cells contain mitochondria, tiny structures often called the cell’s power plants because they generate energy. Mitochondria have their own small set of DNA, separate from the much larger genome in the cell nucleus. Scientists discovered MOTS-c while screening for short protein-coding sequences hidden within the mitochondrial genome. The peptide is produced from a region that was previously thought to only encode a structural component of the mitochondria’s protein-building machinery.
MOTS-c belongs to a class of molecules called mitochondrial-derived peptides. These are small signaling proteins that mitochondria release to communicate with the rest of the body. Once released, MOTS-c enters the bloodstream and acts on distant tissues, particularly skeletal muscle and fat, functioning almost like a hormone.
Effects on Blood Sugar and Insulin
The most studied role of MOTS-c is its effect on metabolism. It works through a chain of cellular events that ultimately activates a key energy-sensing switch inside cells called AMPK. When AMPK turns on, cells ramp up their ability to absorb glucose from the blood. Specifically, MOTS-c promotes the movement of glucose transporters to the surface of muscle cells, allowing them to pull sugar out of the bloodstream more efficiently. This lowers blood sugar levels and reduces the amount of insulin the body needs to produce.
In mice fed a high-fat diet, MOTS-c treatment reduced insulin resistance. Studies in mouse models of diabetes showed it improved glucose tolerance and normalized insulin secretion. It has also shown promise in relieving high blood sugar and insulin resistance in models of gestational diabetes. A Phase 2a clinical trial is currently recruiting adults with prediabetes and overweight or obesity to test whether MOTS-c can improve insulin sensitivity in humans, though results are not yet available.
MOTS-c and Exercise
One of the more striking findings is that exercise naturally boosts MOTS-c levels. In humans, physical activity increases MOTS-c expression both in skeletal muscle and in the bloodstream. This has led researchers to describe MOTS-c as an “exercise mimetic,” a molecule that reproduces some of the benefits of working out.
In mouse studies, the effects were dramatic. When mice were given MOTS-c and put through treadmill tests, 100% of those on the higher dose reached the final sprinting stage (23 meters per minute), compared to just 16.6% of untreated mice. These improvements held across young, middle-aged, and old animals. Body composition changed too: MOTS-c slowed fat gain and increased lean mass in young mice. Perhaps most notably, when treatment was started late in life (the mouse equivalent of old age) and given just three times per week, it still improved physical capacity.
How It Affects Body Fat
MOTS-c influences both types of fat tissue in distinct ways. In white fat, the kind that stores excess calories, MOTS-c promoted a process sometimes called “browning.” This means white fat cells began taking on characteristics of brown fat cells, developing smaller, more numerous fat droplets and increasing their oxygen consumption. Brown fat is metabolically active tissue that burns calories to generate heat rather than storing them.
In brown fat itself, MOTS-c made the tissue denser and reduced the size of fat droplets, signs of increased activation. It boosted the expression of genes responsible for heat production, particularly during cold exposure. Treated mice showed significantly more heat production overall, higher energy expenditure, and less fat accumulation in the liver. In models of diet-induced obesity, MOTS-c treatment improved the excess insulin production and liver fat buildup caused by high-fat feeding.
Bone and Heart Health
MOTS-c appears to play a role in maintaining bone density. It promotes the growth and maturation of bone-building cells while inhibiting the activity of cells that break bone down. In a mouse model of osteoporosis, 12 weeks of MOTS-c treatment increased bone mineral density, bone volume, the number of bone structures called trabeculae, and their thickness. These results suggest it could help counteract bone loss.
Early evidence also points to cardiovascular benefits. MOTS-c has been shown to improve the heart’s mechanical efficiency and both its pumping and relaxation functions, though this area of research is still in its early stages.
The Longevity Connection
One of the most intriguing lines of evidence comes from genetics. Researchers studying Japanese centenarians found that a specific variation in the mitochondrial DNA that encodes MOTS-c was associated with exceptional longevity. This variation, found primarily in Northeast Asian populations, changes one of the 16 amino acids in the MOTS-c peptide. The chemical difference between the original and altered amino acid is significant enough that it likely changes how the peptide functions. This finding suggests that natural variations in MOTS-c may be one biological factor contributing to the unusually high rates of extreme longevity observed in Japan.
The connection makes biological sense. MOTS-c touches many of the same pathways that deteriorate with age: insulin sensitivity, fat metabolism, muscle maintenance, and bone density. By keeping these systems functioning more effectively, a more active version of MOTS-c could plausibly contribute to a longer, healthier life.
Where the Science Stands Now
Nearly all MOTS-c research to date has been conducted in mice or in cells grown in the lab. Animal studies have used doses ranging from 5 to 15 mg/kg per day, delivered by injection. There is no established human dose. The first human clinical trial, testing MOTS-c for insulin sensitivity in adults with prediabetes, is currently in progress. It will track both effectiveness and safety, including adverse events, over 16 weeks. Until those results are published, the peptide’s safety profile in humans remains unconfirmed.
MOTS-c is available through some research peptide suppliers and has gained attention in biohacking and anti-aging communities, but it is not an approved medication in any country. What makes it scientifically interesting is its origin: a tiny molecule from the mitochondrial genome that appears to coordinate metabolism across multiple organ systems, acting as a bridge between the ancient energy-producing machinery inside your cells and whole-body health.